process validation: life cycle approach · current regulatory guidance the expectations for process...
TRANSCRIPT
Process Validation: Life Cycle
Approach
Catherine Neary, GMP Inspector
GMP Conference
7 February 2017
Dublin
Presentation Contents
1• Current Regulatory Landscape & Observations on Annex 15 of EU GMP Guide
2• Considerations for Process Validation (PV) Studies
3• Ongoing Process Verification (OPV)
4• Traditional Approach vs. Quality by Design (QbD)
5• Conclusions
207/02/2017
Definition & Principles of PV
Definition: ‘The documented evidence that the process, operated within
established parameters, can perform effectively and reproducibly to
produce a medicinal product meeting its predetermined specifications and
quality attributes’
Effective process validation contributes significantly to assuring medicinal
product quality
Basic principle of QA that a medicinal product should be produced that is
fit for its intended use
07/02/2017 3
407/02/2017
Definition & Principles of PV
• Quality, safety & efficacy are designed or built into the product
• Quality cannot be adequately assured merely by in-process & finished product inspection or testing
• Each step of the manufacturing process is controlled to assure that the finished product meets all design characteristics & quality attributes including specifications
This principle incorporates the understanding that the following conditions exist:
Current Regulatory Guidance
The expectations for process validation and process control have changed and are continuing
to change, for the better
An enhanced, risk and science based approach is encouraged, in addition to, or instead of the
traditional approach
A traditional approach can be accepted but science and risk based (continuous process
verification) approach is encouraged for the better control over the manufacturing process
The implementation of ICH Q8 “Pharmaceutical Development”, ICH Q9 “Quality Risk
Management” & ICH Q10 “Pharmaceutical Quality Systems” sets the framework for a life
cycle approach to process validation
Considering simply three batches for the process validation shall not confirm the process
consistency
07/02/2017 5
Current Regulatory Guidance
To verify the process consistency and the product quality there should be a science
and risk based rationale for the no. of batches to be selected for the process
validation
Before going to the process validation, the product requirements should be well
understood, and the process should be developed in line to the product
requirements. After development of the process, the process should be well
understood before going for the commercialisation
Process validation should establish whether all quality attributes and process
parameters, which are considered important for ensuring the validated state and
acceptable product quality, can be consistently met by the process
07/02/2017 6
Current Regulatory Guidance
The basis by which process parameters and quality attributes were identified as being critical or non-critical should be clearly documentedtaking into account the results of risk assessment activities
There are 3 approaches to the process validation
After completion of process validation ongoing process verification should be done whatever the approach for the process validation
07/02/2017 7
Lifecycle Concept
07/02/2017 8
Maintenance
of process in
state of control
during routine
production
Product & Process
Development
Qualification of
commercial
manufacturing
process
Definitions
• ‘An alternative approach to process validation in which manufacturing process
performance is continuously monitored and evaluated’
Continuous Process Verification
• ‘A product development approach where set points and operating ranges for process
parameters are defined to ensure reproducibility’
Traditional Approach
• ‘A development approach where risk management and scientific knowledge is
used to identify and understand the material attributes and process parameters
which influence the critical quality attributes of a product’
Enhanced Approach
07/02/2017 9
Considerations for PV Studies
Process Development
• Traditional Approach
• Continuous Verification Approach
• Hybrid Approach
For all products irrespective of the approach used:
• Process knowledge should be accessible to the manufacturing site
• Ongoing process verification during lifecycle is applicable
• Critical Process Parameters (CPPs), Critical Quality Attributes (CQAs),In-process Control Tests should be identified, explained and justifiedusing the principles of Quality Risk Management (QRM)
07/02/2017 10
Considerations for PV Studies - Process Design
Considerations for Manufacturers:
• Collate and assess prior knowledge to understand materials, process and product with
their impact, based on experience obtained from similar processes, development studies,
technology transfer activities, manufacturing experience etc.
• Risk assess process steps and variables; process variables should be gleaned from
process design
• Understand the sources of variation; understanding and controlling process variation
is key
• Understand the impact of variation on the process and ultimately on product attributes
• Control the variation in a manner commensurate with the risk it represents to the
process and product
07/02/2017 11
Considerations for PV Studies - Process Design
Considerations for Manufacturers continued:
• Focus on the critical parts of the process
• Evaluate all attributes (e.g. quality, product, raw material/component) in terms
of their roles in the process and impact on the product or in-process material
• Evaluate all parameters (e.g. process, operating, and equipment) in terms of
their roles in the process and impact on the product or in-process material
• Re-evaluate as new information becomes available
• Ensure all CPPs are identified during risk assessment
• Process control is assured through process design, not testing
07/02/2017 12
Considerations for PV Studies
Process Validation
• The use of risk assessments for validation should be defined in detail;
they should be repeated, as required, in light of increased
knowledge and understanding
• Number of validation batches made, number of samples taken &
sampling locations should be based on QRM principles, with
rationale documented in the protocols
• There should be appropriate checks incorporated into qualification
and validation work to ensure the integrity of all data obtained
07/02/2017 13
Considerations for PV Studies
The number of batches can depend on several factors including:
• the complexity of the process/product being validated
• the level of process variability
• the amount of experimental data and/or process
knowledge/understanding available on the specific process
• production volumes
• More variability ⋙ more runs
• More uncertainty ⋙ more runs
07/02/2017 14
Considerations for PV Studies - Process Validation (continued)
Concurrent validation:
• under special circumstances concurrent release of PV
batches may be acceptable
• must be strong benefit risk ratio for patient, e.g.
• infrequently manufactured (orphan drugs)
• short half lives
• drug shortage
07/02/2017 15
Considerations for PV Studies
EMA Guideline on PV for regulatory submissions – standard vs. non-standard methods of
manufacture:
• Relevant to processes validated using traditional approach
• Process validation scheme to be followed should be included in the dossier
• Production scale validation data should be included in the dossier for biological/biotech
products or where applicant is proposing a non-standard method of manufacture. Data on a
minimum of 3 production scale batches should be submitted, unless otherwise justified
• Designation of a process as non-standard is determined by a combination of:
• nature of active substance, nature of finished product, actual process itself and the
production experience of the manufacturer
• all biological products are considered to be non-standard
• examples included in Annex II of the guideline
07/02/2017 16
Ongoing Process Verification (OPV)
A new regular GMP requirement; applicable also to the traditional approach
It is a monitoring process to confirm that a state of control is maintained
throughout the product lifecycle
A system for detecting unplanned departures or unintended process variability fromthe process as designed
07/02/2017 17
• ‘Documented evidence that the process remains in a state
of control during commercial manufacture’
Definition.....
Ongoing Process Verification (OPV)
How frequent?
How many batches?
Review periodically
The number of process runs should be sufficient to allow the normal extent of
variation and trends to be established to provide sufficient data for evaluation
The product lifecycle stage should be considered
A new product where process knowledge is limited should be reviewed more
frequently than a mature product
07/02/2017 18
Ongoing Process Verification (OPV)
Process trends should be evaluated
• This could be done in conjunction with the annual
Product Quality Review (PQR), if appropriate
• A formal statement in the PQR on OPV may be sufficient
• The relationship between a PQR and the use of OPV
needs to be defined in a procedure or perhaps in the
VMP
07/02/2017 19
Ongoing Process Verification (OPV)
Execute according to protocol & report - if the PQR is appropriate then a protocol may not be required
Protocol may be of benefit for:
a new product where the PQR has not yet been completed and the status of control is being assessed, e.g. after 6 months
For significant changes to products, where specific trends are noted and further information is required to be generated
07/02/2017 20
Ongoing Process Verification (OPV)
Statistical tools should be used to support any conclusions
regarding variability and capability of process, e.g. Cpk or Ppk
Impact on OPV should be considered as part of the change
control process or where incremental change may have an impact
Necessity for additional actions (e.g. enhanced sampling) should
be assessed, e.g. in case of individual or successive incremental
changes; this should be done under a protocol
07/02/2017 21
Ongoing Process Verification – Incorporate Knowledge Management
Knowledge
Management
Process validation studies
Manufacturing experience
/ history; trend data; in-
process control data
Internal & vendor audits,
change controls,
deviations, technical
investigations, CAPA
reports, product quality
reviews, complaints,
adverse events, recall
information
Raw material testing data,
finished product testing
data, stability data, OOS
results
07/02/2017 22
Traditional Approach vs. QbD
A number of Marketing Authorisation Application (MAA) submissions using QbD
Various levels of QbD – from very simple approaches (e.g. control of one step) up to the
full Active Substance/Finished Product QbD involving Process Analytical Technology (PAT)
and Real Time Release (RTR)
A number of MAAs with some level of QbD/PAT/RTR have been approved in the period
2005-2016
Initiated in 2011, to work towards harmonising QbD/PAT approach and to reduce
regulatory burden on industry, EMA and US FDA jointly assessed one MAA as part of a
pilot project
07/02/2017 23
Traditional Approach vs. QbD
In April 2014, EMA and US FDA agreed on a two-year extension of their
joint pilot programme for the parallel evaluation of QbD applications
Majority of MAAs with QbD/PAT concepts have been New Chemical
Entities (NCEs) compared to very small number of established products
New products not registered using Irish sites, therefore no experiences
to share regarding pre-approval inspections in the territory
07/02/2017 24
Conclusions
• Aligns process validation activities with product lifecycle
concept
• Reflects changed manufacturing & regulatory environment
• No longer a one-off exercise (i.e. 3 validation batch approach);
over the lifecycle rather than a one time event
• Incorporates QRM Principles and Knowledge Management
• Came into operation – 1 October 2015
Revised Annex
07/02/2017 25
Final Thoughts
A true lifecycle approach to process validation requires gathering useful,
scientific information as process and control strategies are developed, thus
saving time and resources during later qualification and validation stages
The key is better understanding of the process, its sources of variation and their
control, and the correlation between validation studies, sampling plans,
process performance, product quality, and ongoing process verification
A need for critical thinking and focus on manufacturing science
07/02/2017 26
Final Thoughts
• If something has not happened yet, it will likely not happen…
• If something has not been cited during an inspection, it must be OK…
• People related problems are the result of people making mistakes…
Beware of common process control misconceptions
07/02/2017 27
Regulatory References
• EU GMP Guide Annex 15 : Qualification and Validation (2015)
• EMA Guideline on process validation for finished products –information and data to be provided in regulatory submissions(2016)
• US FDA Guidance for Industry Process Validation: General Principlesand Practices (2011)
• ICH Q8 – Pharmaceutical Development
• ICH Q9 – Quality Risk Management
• ICH Q10 – Pharmaceutical Quality System
• ICH Q11 – Development and Manufacture of Drug Substances
07/02/2017 28